TABLE 2.
Pathological and immunological findings
| Case 1 | Case 2 | Case 3 | ||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| Pathological diagnosis | CA-TCMR IA | CA-TCMR IB | CA-TCMR IA | No rejection | CA-TCMR IA | No rejection |
| Postoperative d | 378 | 574 | 376 | 571 | 404 | 815 |
| Banff lesion score (0–3) | ||||||
| ti | 2 | 2 | 2 | 0 | 3 | 0 |
| i | 0 | 1 | 1 | 0 | 1 | 0 |
| i-IF/TA | 3 | 2 | 2 | 0 | 3 | 0 |
| t | 2 | 3 | 2 | 0 | 2 | 0 |
| g | 0 | 0 | 0 | 0 | 0 | 0 |
| v | 0 | 0 | 0 | 0 | 0 | 0 |
| ci | 3 | 2 | 3 | 0 | 3 | 0 |
| ct | 3 | 2 | 3 | 1 | 3 | 1 |
| cv | 2 | 3 | 0 | 0 | 3 | 3 |
| ah | 0 | 0 | 1 | 0 | 1 | 1 |
| aah | 0 | 0 | 0 | 0 | 1 | 0 |
| ptc | 0 | 0 | 0 | 0 | 0 | 0 |
| C4d | 1 | 0 | 1 | 0 | 0 | 0 |
| PRA class I/II | 0%/0% | 0%/0% | 0%/0% | 0%/0% | 1.8%/0% | 1.8%/0% |
| De novo DSA | Negative | Negative | Negative | Negative | Negative | Negative |
Pathological diagnoses were based on the 2017 Banff classification.
CA-TCMR, chronic-active T cell-mediated rejection; DSA, donor-specific anti-HLA antibody; i-IF/TA, interstitial inflammation in sclerotic cortical parenchyma; PRA, panel reactive antibody.